King B - Search Results

1

The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Peterson D, Damsky W, King B. Peterson D, et al. Among authors: king b. J Am Acad Dermatol. 2020 Jun;82(6):e223-e226. doi: 10.1016/j.jaad.2020.03.099. Epub 2020 Apr 9. J Am Acad Dermatol. 2020. PMID: 32278797 Free PMC article. No abstract available.

2

Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.

Craiglow BG, King BA. Craiglow BG, et al. JAMA Dermatol. 2015 Oct;151(10):1110-2. doi: 10.1001/jamadermatol.2015.1520. JAMA Dermatol. 2015. PMID: 26107994

3

Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.

Levy LL, Urban J, King BA. Levy LL, et al. J Am Acad Dermatol. 2015 Sep;73(3):395-9. doi: 10.1016/j.jaad.2015.06.045. Epub 2015 Jul 17. J Am Acad Dermatol. 2015. PMID: 26194706

4

Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis.

Dhayalan A, King BA. Dhayalan A, et al. JAMA Dermatol. 2016 Apr;152(4):492-3. doi: 10.1001/jamadermatol.2015.3772. JAMA Dermatol. 2016. PMID: 26630079 No abstract available.

5

STATing the obvious: it's time for new treatments in atopic dermatitis.

Damsky W, King BA. Damsky W, et al. Among authors: king ba. Br J Dermatol. 2016 Nov;175(5):861-862. doi: 10.1111/bjd.15036. Br J Dermatol. 2016. PMID: 27790697 No abstract available.

6

Tofacitinib for the treatment of alopecia areata and variants in adolescents.

Craiglow BG, Liu LY, King BA. Craiglow BG, et al. J Am Acad Dermatol. 2017 Jan;76(1):29-32. doi: 10.1016/j.jaad.2016.09.006. Epub 2016 Nov 2. J Am Acad Dermatol. 2017. PMID: 27816292

7

Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.

Liu LY, Craiglow BG, Dai F, King BA. Liu LY, et al. J Am Acad Dermatol. 2017 Jan;76(1):22-28. doi: 10.1016/j.jaad.2016.09.007. Epub 2016 Nov 2. J Am Acad Dermatol. 2017. PMID: 27816293

8

Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.

King B, Lee AI, Choi J. King B, et al. J Invest Dermatol. 2017 Apr;137(4):951-954. doi: 10.1016/j.jid.2016.10.044. Epub 2016 Nov 22. J Invest Dermatol. 2017. PMID: 27887955 Free PMC article. No abstract available.

9

Idiopathic erythema multiforme: Evidence of underlying Janus kinase-signal transducer and activator of transcription activation and successful treatment with tofacitinib.

Damsky W, King BA. Damsky W, et al. JAAD Case Rep. 2016 Dec 7;2(6):502-504. doi: 10.1016/j.jdcr.2016.10.009. eCollection 2016 Nov. JAAD Case Rep. 2016. PMID: 28004029 Free PMC article. No abstract available.

10

JAK inhibitors in dermatology: The promise of a new drug class.

Damsky W, King BA. Damsky W, et al. J Am Acad Dermatol. 2017 Apr;76(4):736-744. doi: 10.1016/j.jaad.2016.12.005. Epub 2017 Jan 28. J Am Acad Dermatol. 2017. PMID: 28139263 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,055 results

Search Page

Filters